Award of Anthim (obiltoxaximab) 600mg/6ml for Injection
Award Notice Posted
A later notice was posted: the Limited / Sole Source Justification from .
- Solicitation number
- 75A50121R00041
- Agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Awarded
- to Elusys Therapeutics Inc.
- Set-aside
- No set-aside
Opportunity facts
- Contract number
- 75A5012100073 Federal contract award
- NAICS code
- Not on record
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- Parsippany, New Jersey 07054, United States
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response awarded a sole source firm fixed price letter contract to Elusys Therapeutics, Inc. for the manufacture of and vendor managed inventory including rotation and cold-chain distribution services for the FDA approved Anthrax antitoxin pharmaceutical Anthim (obiltoxaximab) Injection. The contract was awarded on August 6, 2021 and definitized on January 12, 2022, with a period of performance from August 6, 2021 through February 25, 2023 and a total contract value of $80,864,000.
Notice text
The Office of the Assistant Secretary for Preparedness and Response (ASPR), Division of Strategic National Stockpile (DSNS) awarded a sole source Firm Fixed Price letter contract to Elusys located at
Elusys Therapeutics, Inc., 4 Century Drive, Suite 260, Parsippany NJ 07054, for the Manufacture of and Vendor Managed Inventory (VMI) (include rotation, and cold-chain distribution services) for the FDA approved Anthrax Antitoxin pharmaceutical, Anthim (obiltoxaximab) Injection.
This action was posted at SAM.gov. The selection of this offeror was based on the criteria contained in the RFP under E-Evaluation Factors for Award. The letter contract was awarded on 8-6-2021 and definitized on 1/12/2022. The period of performance is 8-6-2021-2/25/2023. The total contract value is $80,864,000.00.
Awarded contract 75A5012100073 to Elusys Therapeutics, Inc. for 80864000.00 on 2022-01-12.
Notice history
| Notice | Type | Posted |
|---|---|---|
| Award of Anthim (obiltoxaximab) 600mg/6ml for Injection | Limited / Sole Source Justification | |
| This notice | Award Notice | |
| Award of Anthim (obiltoxaximab) 600mg/6ml for Injection | Pre-Solicitation |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity